Abstract | INTRODUCTION:
Rheumatoid arthritis (RA) is a chronic, painful and debilitating autoimmune disease. Although the outcome for patients with RA has improved markedly in the past decades, adequate disease control cannot be achieved in a substantial proportion of patients. Since RA is a syndrome with different biological subsets, new drugs with a novel mechanism of action may represent a valuable addition to the current armamentarium. AREAS COVERED: This review focuses on the pharmacodynamics and pharmacokinetics of atacicept . Furthermore, the article both summarises and comments on the drug's efficacy and safety profile in RA patients. EXPERT OPINION:
|
Authors | Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke, Bernard Bannwarth |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 23
Issue 9
Pg. 1285-94
(Sep 2014)
ISSN: 1744-7658 [Electronic] England |
PMID | 25078871
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antirheumatic Agents
- B-Cell Activating Factor
- Recombinant Fusion Proteins
- Tumor Necrosis Factor Ligand Superfamily Member 13
- TACI receptor-IgG Fc fragment fusion protein
|
Topics |
- Animals
- Antirheumatic Agents
(adverse effects, pharmacology, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy, physiopathology)
- B-Cell Activating Factor
(metabolism)
- B-Lymphocytes
(metabolism)
- Cell Survival
(drug effects)
- Humans
- Recombinant Fusion Proteins
(adverse effects, pharmacology, therapeutic use)
- Tumor Necrosis Factor Ligand Superfamily Member 13
(metabolism)
|